Biomea Fusion Inc (BMEA)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$0.60+2.58%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Biomea Fusion Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	0
EPS	—	-0.29
Annual ending 2026-12-31
Revenue	—	3M
EPS	—	-0.736
Annual ending 2027-12-31
Revenue	—	1.12M
EPS	—	-0.767

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Advance COVALENT-112 trial for icovamenib in type 1 diabetes	Biomea Fusion is advancing its key drug trial for type 1 diabetes.	Intact	Trial progress stalls or negative trial results reported	COVALENT-112 trial advancing (52% C-peptide AUC increase reported Apr 2026) Positive Phase 2 results (52% C-peptide increase) and recent Phase I reporting confirm trial progress is on track. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Deliver 26-week primary endpoint data for T2D diabetes treatment	Biomea Fusion is advancing its key drug trial for type 1 diabetes.	Intact	Data delayed or negative results reported	Qualitative condition This condition has no defined numerical measure. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Maintain cash runway into Q1 2027	The company has maintained a cash runway into early 2027.	Intact	Cash runway falls short of Q1 2027	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated in 2 of 2 supplied transcript quarters. Cash, cash equivalents, and restricted cash were $45.1 million at March 31, 2026 and $35.2 million at June 30, 2026, while projected runway moved from the first to the second quarter of 2027. The cash balance declined as the stated runway extended; this indicates some progress on the runway commitment, alongside continued cash use. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPSUnavailable

Unavailable → Unavailable · observed estimates

FY2027 revenue$0.00B

$0.00B → $0.00B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	$0	4 / 6
2026-07-25	Unavailable	$0	4 / 6
2026-07-26	Unavailable	$0	4 / 6
2026-07-27	Unavailable	$0	4 / 6
2026-07-28	Unavailable	$0	4 / 6
2026-07-29	Unavailable	$0	4 / 6
2026-07-30	Unavailable	$0	4 / 6
2026-07-31	Unavailable	$0	4 / 6
2026-08-01	Unavailable	$0	4 / 6
2026-08-02	Unavailable	$0	4 / 6
2026-08-03	Unavailable	$0	4 / 6
2026-08-04	Unavailable	$0	4 / 6
2026-08-05	Unavailable	$0	4 / 6
2026-08-06	Unavailable	$0	4 / 6
2026-08-07	Unavailable	$1,117,179	4 / 6
2026-08-08	Unavailable	$0	4 / 6
2026-08-09	Unavailable	$0	4 / 6
2026-08-10	Unavailable	$0	4 / 6
2026-08-11	Unavailable	$0	4 / 7
2026-08-12	Unavailable	$0	4 / 7
2026-08-13	Unavailable	$0	4 / 7
2026-08-14	Unavailable	$1,117,179	4 / 6
2026-08-15	Unavailable	$1,117,179	4 / 6
2026-08-16	Unavailable	$1,117,179	4 / 6
2026-08-17	Unavailable	$1,117,179	4 / 6
2026-08-18	Unavailable	$1,117,179	4 / 6
2026-08-19	Unavailable	$1,117,179	4 / 6
2026-08-20	Unavailable	$1,117,179	4 / 7
2026-08-21	Unavailable	$1,117,179	4 / 7
2026-08-22	Unavailable	$1,117,179	4 / 7
2026-08-23	Unavailable	$1,117,179	4 / 7
2026-08-24	Unavailable	$1,117,179	4 / 7
2026-08-25	Unavailable	$1,117,179	4 / 7
2026-08-26	Unavailable	$1,117,179	4 / 7
2026-08-27	Unavailable	$1,117,179	4 / 7
2026-08-28	Unavailable	$1,117,179	4 / 7
2026-08-29	Unavailable	$1,117,179	4 / 7
2026-08-30	Unavailable	$1,117,179	4 / 7
2026-08-31	Unavailable	$1,117,179	4 / 7
2026-09-01	Unavailable	$1,117,179	4 / 7
2026-09-02	Unavailable	$1,117,179	4 / 7
2026-09-03	Unavailable	$1,117,179	4 / 7
2026-09-04	Unavailable	$1,117,179	4 / 7
2026-09-05	Unavailable	$1,117,179	4 / 7
2026-09-06	Unavailable	$1,117,179	4 / 7
2026-09-07	Unavailable	$1,117,179	4 / 7
2026-09-08	Unavailable	$1,117,179	4 / 7
2026-09-09	Unavailable	$1,117,179	4 / 7
2026-09-10	Unavailable	$1,117,179	4 / 7
2026-09-11	Unavailable	$1,117,179	4 / 7
2026-09-12	Unavailable	$1,117,179	4 / 7
2026-09-13	Unavailable	$1,117,179	4 / 7
2026-09-14	Unavailable	$1,117,179	4 / 7
2026-09-15	Unavailable	$1,117,179	4 / 7
2026-09-16	Unavailable	$1,117,179	4 / 7
2026-09-17	Unavailable	$1,117,179	4 / 7
2026-09-18	Unavailable	$1,117,179	4 / 7
2026-09-19	Unavailable	$1,117,179	4 / 7
2026-09-20	Unavailable	$1,117,179	4 / 7
2026-09-21	Unavailable	$1,117,179	4 / 7
2026-09-22	Unavailable	$1,117,179	4 / 7
2026-09-23	Unavailable	$1,117,179	4 / 7
2026-09-24	Unavailable	$1,117,179	4 / 7
2026-09-25	Unavailable	$1,117,179	4 / 7
2026-09-26	Unavailable	$1,117,179	4 / 7
2026-09-27	Unavailable	$1,117,179	4 / 7
2026-09-28	Unavailable	$1,117,179	4 / 7
2026-09-29	Unavailable	$1,117,179	4 / 7
2026-09-30	Unavailable	$1,117,179	4 / 7
2026-10-01	Unavailable	$1,117,179	4 / 7
2026-10-02	Unavailable	$1,117,179	4 / 7
2026-10-03	Unavailable	$1,117,179	4 / 7
2026-10-04	Unavailable	$1,117,179	4 / 7
2026-10-05	Unavailable	$1,117,179	4 / 7
2026-10-06	Unavailable	$1,117,179	4 / 7
2026-10-07	Unavailable	$1,117,179	4 / 7
2026-10-08	Unavailable	$1,117,179	4 / 7
2026-10-09	Unavailable	$1,117,179	4 / 8
2026-10-10	$-0.98	$1,117,179	5 / 8
2026-10-11	$-0.98	$1,117,179	5 / 8
2026-10-12	$-0.98	$1,117,179	5 / 8
2026-10-13	$-0.98	$1,117,179	5 / 8
2026-10-14	$-0.98	$1,117,179	5 / 8
2026-10-15	$-0.98	$1,117,179	5 / 8
2026-10-16	$-0.98	$1,117,179	5 / 8
2026-10-17	$-0.98	$1,117,179	5 / 8
2026-10-18	Unavailable	$1,117,179	4 / 7
2026-10-19	Unavailable	$1,117,179	4 / 7
2026-10-20	Unavailable	$1,117,179	4 / 7
2026-10-21	Unavailable	$1,117,179	4 / 7
2026-10-22	Unavailable	$1,117,179	4 / 7
2026-10-23	Unavailable	$1,117,179	4 / 7
2026-10-24	Unavailable	$1,117,179	4 / 7

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Sell*
2026-05-01	7	1
2026-06-01	6	1
2026-07-01	6	1
2026-08-01	6	1
2026-09-01	6	1
2026-10-01	7	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 7 Buy / Strong Buy · 0 Hold · 1 Sell / Strong Sell

0 upgrades0 downgrades2 maintains

Recent actions · Sep 25–Oct 24 · 2 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Deliver 26-week primary endpoint data for T2D diabetes treatmentQualitative condition
Maintain cash runway into Q1 2027Direct metric needs a verified mapping

Next proof point

Nov 3, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.4%Typical daily move · historical

Downside history

-73.5%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Biomea Fusion Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is speculative growth, not a profitable or established business: BMEA has no reported revenue and is developing programs for diabetes and obesity. The long-term thesis is intact in the snapshot, but confidence is low and the overall signal is mixed.

What's priced into Biomea Fusion Inc

The valuation measure fell from 63.8 to 37.0, a 26.8-point decline, while the signal shifted from mildly favorable to mixed and the risk label rose to high. The snapshot gives no peer comparison or direct account of market expectations, so whether the valuation is cheap, fair, or expensive is unclear.

What the fundamentals likely do

Near term, results have been described as holding in the top half of the industry, and two recent earnings events were labeled positive. The quarterly net loss narrowed, but BMEA remains loss-making and the clinical programs are still in development, with limited evidence of delivery on management priorities. Cash declined between March and June 2026, though management's stated runway moved into the second quarter of 2027; next-print risk is elevated, with a 44% miss probability in the snapshot.

What Biomea Fusion Inc hinges on

The multi-year view depends on progress in the icovamenib diabetes trials and BMF-650 obesity program, for which the supplied evidence does not establish clinical outcomes or commercial progress. Near term, a guidance cut is a stated negative trigger, while continued earnings strength and higher guidance from sector bellwethers are possible supports. Weaker jobs data could also weigh on the sector, according to the snapshot.